Literature DB >> 23113663

Short communication: fasting increases serum concentrations of bilirubin in patients receiving atazanavir: results from a pilot study.

Gustavo Lopardo1, Emiliano Bissio, Lidia Espinola, Paula Gallego, Marcela Stambullian, Adrián Gadano.   

Abstract

Unconjugated hyperbilirubinemia resulting from therapy with atazanavir is physiologically related to hyperbilirubinemia in Gilbert's syndrome (GS). In patients with GS, changes in diet have a significant impact on bilirubinemia. Our aim was to investigate whether changes in diet affect the level of serum bilirubin in patients receiving atazanavir. Thirty patients on stable therapy with ritonavir-boosted atazanavir without evidence of GS were enrolled. Hemolysis and chronic hepatitis were excluded. After a baseline period of normal intake of calories, the patients were randomized to follow a 24-h 400-calorie diet (fasting), then a 48-h period of normal calorie intake and, afterward, a 24-h period of a high-calorie diet, or the same interventions in inverse order. Serum bilirubin concentrations were measured before and after each intervention. A high adherence to the recommended diet was observed. The mean unconjugated bilirubin concentration before the high-calorie diet was 2.79±1.53 mg/dl and after such intervention it was 2.70±1.40 mg/dl. The mean difference between preintervention and postintervention was -0.08±0.69 mg/dl (p=NS). The mean unconjugated bilirubin concentration before the fasting diet was 2.31±1.23 mg/dl and it was 3.84±1.90 mg/dl after. The mean difference between prefasting and postfasting was 1.53±1.17 mg/dl (p=0.001). According to these results, short periods of fasting seem to increase the unconjugated bilirubin concentration in patients on atazanavir. A high-calorie diet did not have any impact in bilirubin probably because most patients follow similar diets in their everyday life.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23113663      PMCID: PMC3581034          DOI: 10.1089/aid.2012.0232

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  21 in total

1.  Role of UGT1A1 mutation in fasting hyperbilirubinemia.

Authors:  T Ishihara; M Kaito; K Takeuchi; E C Gabazza; Y Tanaka; K Higuchi; J Ikoma; S Watanabe; H Sato; Y Adachi
Journal:  J Gastroenterol Hepatol       Date:  2001-06       Impact factor: 4.029

2.  Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.

Authors:  Ian Sanne; Peter Piliero; Kathleen Squires; Alexandra Thiry; Steven Schnittman
Journal:  J Acquir Immune Defic Syndr       Date:  2003-01-01       Impact factor: 3.731

3.  Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype.

Authors:  Tim O Lankisch; Ulrike Moebius; Michael Wehmeier; Georg Behrens; Michael P Manns; Reinhold E Schmidt; Christian P Strassburg
Journal:  Hepatology       Date:  2006-11       Impact factor: 17.425

4.  Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1.

Authors:  Sonia Rodríguez Nóvoa; Pablo Barreiro; Ana Rendón; Ana Barrios; Angélica Corral; Inmaculada Jiménez-Nacher; Juan González-Lahoz; Vincent Soriano
Journal:  Clin Infect Dis       Date:  2005-12-08       Impact factor: 9.079

5.  Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel.

Authors:  Melanie A Thompson; Judith A Aberg; Pedro Cahn; Julio S G Montaner; Giuliano Rizzardini; Amalio Telenti; José M Gatell; Huldrych F Günthard; Scott M Hammer; Martin S Hirsch; Donna M Jacobsen; Peter Reiss; Douglas D Richman; Paul A Volberding; Patrick Yeni; Robert T Schooley
Journal:  JAMA       Date:  2010-07-21       Impact factor: 56.272

6.  Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.

Authors:  Jose Gatell; Dominique Salmon-Ceron; Adriano Lazzarin; Eric Van Wijngaerden; Francisco Antunes; Clifford Leen; Andrzej Horban; Victoria Wirtz; Linda Odeshoo; Monique Van den Dungen; Claudia Gruber; Emilio Ledesma
Journal:  Clin Infect Dis       Date:  2007-04-25       Impact factor: 9.079

Review 7.  Clinical pharmacology, efficacy and safety of atazanavir: a review.

Authors:  Danièle Bentué-Ferrer; Cédric Arvieux; Olivier Tribut; Annick Ruffault; Eric Bellissant
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-11       Impact factor: 4.481

8.  Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts.

Authors:  C Torti; G Lapadula; A Antinori; T Quirino; R Maserati; F Castelnuovo; F Maggiolo; A De Luca; G Paraninfo; F Antonucci; G Migliorino; A Lazzarin; G Di Perri; G Rizzardini; R Esposito; G Carosi
Journal:  Infection       Date:  2009-05-26       Impact factor: 3.553

Review 9.  Efficacy and safety of once-daily regimens in the treatment of HIV infection.

Authors:  Jean-Michel Molina
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 10.  Atazanavir: new option for treatment of HIV infection.

Authors:  Diane V Havlir; Steven D O'Marro
Journal:  Clin Infect Dis       Date:  2004-05-13       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.